[Chemotherapy of metastatic urothelial carcinoma].
Six patients with metastatic urothelial carcinoma--4 transitional cell carcinomas and 2 adenocarcinomas--were treated with cis-platinum (CDDP), adriamycin (ADM) and 5-fluorouracil (5-FU). CDDP (12-15 mg/m2) and 5-FU (300 mg/m2) were given on day 1-5 and ADM (30 mg/m2) was given on day 1. Courses were repeated every 3-4 weeks. In 4 cases of transitional cell carcinoma, 1 complete remission and 3 partial remissions, were obtained, but in 2 cases of adenocarcinoma, only symptomatic improvement was observed. General toxic effects consisted of vomiting, alopecia, myelosuppression and disturbance of renal function, but the therapy was well tolerated. Our encouraging results to date seemed to indicate the higher degree of effectiveness of this combination chemotherapy against the chemoresistant disease.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage*; D004317:Doxorubicin / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D014571:Urologic Neoplasms / Q000188:drug therapy*
D004317:Doxorubicin; D002945:Cisplatin; D005472:Fluorouracil